Goldman Sachs starts coverage on ResMed with "buy" rating
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
ResMed initiated with a Buy at Goldman Sachs
Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
'I had no idea I was seriously ill until I drove off the motorway into a tree'
Dave hadn't felt well before but had been told it was down to smoking, shift work, allergies, poor diet - and even his pillow ...
Fintel on MSN5d
Piper Sandler Initiates Coverage of ResMed (RMD) with Neutral Recommendation
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed (NYSE:RMD) with a Neutral recommendation.
Fintel on MSN6d
Piper Sandler Initiates Coverage of ResMed Inc. - Depositary Receipt () (RSMDF) with Neutral Recommendation
Fintel reports that on January 10, 2025, Piper Sandler initiated coverage of ResMed Inc. - Depositary Receipt () (OTCPK:RSMDF ...
Balanced Outlook on ResMed: Strong Execution and Innovations Offset by Valuation Concerns and Market Challenges
Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...